Catalyst Pharmaceuticals, Inc. (FRA:CN2)

Germany · Delayed Price · Currency is EUR

19.51

-0.04 (-0.18%)

Last updated: Dec 5, 2025, 8:04 AM CET

-7.75% (1Y)

Market Cap	2.43B
Revenue (ttm)	492.80M
Net Income (ttm)	185.43M
Shares Out	n/a
EPS (ttm)	1.46
PE Ratio	13.12
Forward PE	9.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	171
Open	19.51
Previous Close	19.55
Day's Range	19.51 - 19.51
52-Week Range	16.15 - 24.00
Beta	n/a
RSI	52.88
Earnings Date	Feb 26, 2026

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatmen... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2002

Employees 181

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol CN2

Full Company Profile

Financial Performance

In 2024, Catalyst Pharmaceuticals's revenue was $491.73 million, an increase of 23.49% compared to the previous year's $398.20 million. Earnings were $163.89 million, an increase of 129.50%.

Financial numbers in USD Financial Statements

News

There is no news available yet.